Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
CNBC
Read Full Article at CNBC →Ad Slot — In-Article (728x90)
Its latest fundraising round provides the French biotech with enough cash to finance operations through 2029.
This is a summary. For the full story, read the original article at CNBC.
Original source: CNBC